Priya Mande has nearly 30 years of experience in the pharmaceutical and biotech sector, 12 of which were at Glaxo Wellcome and GlaxoSmithKline where she latterly supported the R&D Executive. She has held roles across research, development, finance and business strategy & operations. She was previously at PowderMed responsible for delivery of the vaccine immunotherapeutic portfolio. Priya was the Vaccine Research Project Leader for Influenza at Pfizer before becoming Chief Operating Officer of Hybrid BioSystems in 2009 which then formed PsiOxus Therapeutics in 2010. She joined the PsiOxus Board of Directors in 2016. Over 10 years she has overseen the growth of PsiOxus in the UK and USA holding responsibility for corporate development, project management, clinical, finance, legal and operations. Priya studied Applied Biochemistry at Brunel University London and received her MBA with distinction from the London Business School. She was awarded Chartered Director status in 2020 by the UK Institute of Directors.